GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Other Income (Minority Interest)

Artgen Biotech PJSC (MIC:ABIO) Other Income (Minority Interest) : ₽24 Mil (TTM As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Other Income (Minority Interest)?

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary. Artgen Biotech PJSC's Other Income (Minority Interest) for the six months ended in Jun. 2023 was ₽-4 Mil. Its Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Jun. 2023 was ₽24 Mil.


Artgen Biotech PJSC Other Income (Minority Interest) Historical Data

The historical data trend for Artgen Biotech PJSC's Other Income (Minority Interest) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC Other Income (Minority Interest) Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Income (Minority Interest)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.97 -26.78 -30.55 -21.92 23.04

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Income (Minority Interest) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.13 -15.78 -4.91 27.95 -4.19

Artgen Biotech PJSC Other Income (Minority Interest) Calculation

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary.

Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₽24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Artgen Biotech PJSC  (MIC:ABIO) Other Income (Minority Interest) Explanation

Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company. It is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Artgen Biotech PJSC Business Description

Industry
Traded in Other Exchanges
N/A
Address
Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

Artgen Biotech PJSC Headlines

From GuruFocus

ARCA biopharma Announces Second Quarter 2022 Financial Results

By PurpleRose PurpleRose 08-02-2022

James Flynn Joins ARCA biopharma Board of Directors

By Value_Insider Value_Insider 12-19-2022

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

By GuruFocusNews GuruFocusNews 07-01-2022

ARCA biopharma Announces Third Quarter 2022 Financial Results

By Value_Insider Value_Insider 10-28-2022

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

By PurpleRose PurpleRose 07-11-2022

ARCA biopharma Establishes Special Committee of the Board of Directors

By GuruFocusNews GuruFocusNews 04-18-2022

ARCA biopharma Announces First Quarter 2023 Financial Results

By sperokesalga sperokesalga 04-24-2023